SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

21 Jul 2025 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release by Sun Pharmaceutical Industries (together with its subsidiaries / affiliated companies, ‘Sun Pharma’) about ‘Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint’.

The above information is a part of company’s filings submitted to BSE. 

Sun Pharma. Inds. Share Price

1938.80 -21.20 (-1.08%)
05-Aug-2026 10:05 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.80
Dr. Reddys Labs. 1166.15
Cipla 1448.25
Lupin 2370.15
Zydus Lifesciences 1112.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: